Skip to main content
JADPRO Live 2023 Main banner
Final Program


Conference Brochure
Icon Legend
Presentation Icons
CE credit available
CE credit available
Pharmacology credit available
Pharmacology credit available
Poster session
Poster session

Full Schedule

Full Schedule

  • Thursday, November 9, 2023
  • 7:00 AM – 7:30 PM ET
    Registration
  • 11:00 AM – 2:00 PM ET
    Pre-Conference Seminar: Complex Pain Management: Treating the Patient With Substance Use Disorder and Cancer
  • 12:30 PM – 2:30 PM ET
    Pre-Conference Activity: New to Oncology - Peer Roundtable
  • 2:30 PM – 4:00 PM ET
    Independent CE-Accredited Satellite Symposium
    Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors
  • 4:00 PM – 5:00 PM ET
    Non-CE-Accredited Satellite Symposium: A Treatment Option for Patients with Relapsed or Refractory Multiple Myeloma
    Pfizer Oncology
  • 5:00 PM – 5:45 PM ET
    APSHO Annual Member Meeting
  • 6:00 PM – 7:30 PM ET
    Welcome Reception
  • 6:05 PM – 6:35 PM ET
    Poster Walk
  • Friday, November 10, 2023
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium
    Janssen Oncology invites you to learn more about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
    Janssen: Pharmaceutical Companies of Johnson & Johnson

    Seating available on first-come, first-served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Exelixis Clinical Product Overview for Advanced Practice Providers
    Exelixis

    Seating available on first-come, first-served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Supporting Patients With HR+/HER2- mBC Throughout Their Treatment Journey
    Pfizer Oncology

    Seating available on first-come, first served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Treatment Options for Patients with Unresectable or Metastatic Melanoma​
    Bristol Myers Squibb

    Seating available on first-come, first-served basis
  • 6:30 AM – 6:00 PM ET
    Registration
  • 7:00 AM – 8:00 AM ET
    Exhibit Hall Open & Continental Breakfast
  • 8:00 AM – 8:10 AM ET
    Welcome & Opening Remarks
  • 8:10 AM – 9:15 AM ET
    Opening Panel Discussion
    Advanced Practitioners in Hematology and Oncology: A Call to Action
  • 9:30 AM – 10:15 AM ET
    Optimizing the Care of Patients with Colorectal Cancer in Clinical Practice
  • 9:30 AM – 10:15 AM ET
    The Evolving Landscape of Frontline Therapy in Chronic Lymphocytic Leukemia
  • 10:15 AM – 11:15 AM ET
    Exhibit Hall Open & Refreshment Break
  • 10:15 AM – 6:15 PM ET
    Braindate
  • 10:30 AM – 11:00 AM ET
    APSHO Committee Meet & Greet: Awards & Recognition Committee
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation: An Advancement in Frontline DLBCL
    Genentech
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation: Cosela: A Multilineage Myeloprotection Therapy
    G1 Therapeutics
  • 10:30 AM – 11:30 AM ET
    Exhibit Hall Presentation: Relapsed or Refractory Multiple Myeloma: A Case-based Presentation
    Sanofi
  • 11:15 AM – 12:15 PM ET
    Advancing Precision-Targeted Treatment for Patients with Metastatic Non-Small Cell Lung Cancer
  • 11:15 AM – 12:15 PM ET
    Cardio-Oncology Considerations in Patients With Cancer
  • 12:15 PM – 1:45 PM ET
    Exhibit Hall Open & Lunch
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: A Collaborative Approach to Deciding When to Intervene With Jakafi® (ruxolitinib) For Adults With Polycythemia Vera Who Have Had an Inadequate Response to Hydroxyurea
    Incyte

    Seating available on first-come, first served basis
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: PADCEV® (enfortumab vedotin-ejfv): Use as A Single Agent or In Combination With a PD⁠-⁠1 Inhibitor - 081-1005-PM
    Seagen

    Seating available on first-come, first-served basis
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: The Role of APPs in Maximizing Patient Outcomes with DARZALEX® and DARZALEX® FASPRO® +Rd in Patients with Newly Diagnosed, Transplant-Ineligible Multiple Myeloma.
    Janssen Oncology part of the Pharmaceutical Companies of Johnson & Johnson

    Seating available on first-come, first-served basis
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: Treatment Options for Patients with Resectable and Metastatic Non-Small Cell Lung Cancer​
    Bristol Myers Squibb

    Seating available on first-come, first-served basis
  • 12:30 PM – 1:00 PM ET
    APSHO Committee Meet & Greet: Communications Committee
  • 1:15 PM – 1:45 PM ET
    APSHO Committee Meet & Greet: Diversity, Equity, & Inclusion Committee (DEI)
  • 1:45 PM – 2:45 PM ET
    Keynote Address: We the Patients
  • 2:45 PM – 3:45 PM ET
    Exhibit Hall Open & Refreshment Break
  • 2:45 PM – 3:45 PM ET
    Moderated Posters: Clinical Posters, Industry Encore Posters, & APSHO Patient Perspective Posters
  • 3:00 PM – 3:30 PM ET
    APSHO Committee Meet & Greet: Education Committee
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation
    Bispecific Antibodies in DLBCL: Navigating the Evolving Treatment Landscape
    AbbVie and Genmab
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation: Diagnostic Approach and Considerations in Patients with Hemolytic Anemia
    Agios Pharmaceuticals
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation: Explore the current data that could help you recognize/assess candidates for a CDK4 & 6 inhibitor.
    Eli Lilly and Company
  • 3:45 PM – 4:30 PM ET
    Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs
  • 3:45 PM – 4:30 PM ET
    Unveiling the Impact of Radiation Therapy: Navigating Acute and Long-Term Side Effects for Optimal Patient Care
  • 3:45 PM – 4:45 PM ET
    Oral Poster Presentations
  • 4:45 PM – 5:30 PM ET
    Independent Certified Satellite Symposium Targeted Therapy Approaches for Metastatic Urothelial Carcinoma
  • 5:30 PM – 6:15 PM ET
    Independent Certified Satellite Symposium Treatment Advances with Novel Anti-Androgen Therapy, PARP Inhibitors, and NGI For Hormone-Sensitive and Castration-Resistant Prostate Cancer
  • 6:15 PM – 8:15 PM ET
    Independent CE-Accredited Dinner Satellite Symposium
    Advancing the Myelofibrosis Treatment Paradigm: A Case-Based Collaborative for the Advanced Practitioner in Oncology
  • Saturday, November 11, 2023
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium
    Clinical Considerations for the Treatment of mTNBC and HR+/HER2- mBC with an ADC
    Gilead

    Seating available on first-come, first-served basis

    Seating available on first-come, first-served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: A first in-class NME in 3L+ follicular lymphoma & A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma
    Genentech

    Seating available on first-come, first-served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Learn more about a CAR T cell therapy for relapsed/refractory multiple myeloma (RRMM)
    Bristol Myers Squibb

    Seating available on first-come, first served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Myelofibrosis and Strategies for Disease Management: Key Considerations for Patient Care
    GSK

    Seating available on first-come, first served basis
  • 6:30 AM – 6:30 PM ET
    Registration
  • 7:00 AM – 8:00 AM ET
    Exhibit Hall Open & Continental Breakfast
  • 8:00 AM – 8:15 AM ET
    Opening Remarks & APSHO Fellow (FAPO) Recognition Presentation
  • 8:10 AM – 8:30 AM ET
    The Mary Pazdur Award Presentation
  • 8:25 AM – 9:00 AM ET
    The Annual Mary Pazdur Award Recipient Lecture
  • 9:15 AM – 10:15 AM ET
    Essence of Surgical Oncology: Knowing When and When Not to Operate on Patients With Cancer
  • 9:15 AM – 10:15 AM ET
    New Drug Updates: Solid Tumors
  • 10:15 AM – 11:15 AM ET
    Exhibit Hall Open & Refreshment Break
  • 10:15 AM – 11:15 AM ET
    Moderated Posters: Clinical Posters, Industry Encore Posters, and APSHO Patient Perspective Posters
  • 10:15 AM – 6:15 PM ET
    Braindate
  • 10:30 AM – 11:00 AM ET
    APSHO Committee Meet & Greet: Membership Committee
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation
    The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)
    Blueprint Medicines
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation
    Understanding the role of Advanced Practice Providers in the management of Low-risk Myelodysplastic Syndromes (MDS)
    Bristol Myers Squibb
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation: An Overview of Clinical Data for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in 2L HER2+ Metastatic Breast Cancer
    Daiichi-Sankyo
  • 11:15 AM – 12:15 PM ET
    Benign Hematology Limbo: How Low Is Too Low?
  • 11:15 AM – 12:15 PM ET
    Improving Outcomes for Women with Metastatic HER2-Positive Breast Cancer
  • 12:15 PM – 1:45 PM ET
    Exhibit Hall & Lunch
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: A Discussion of a Real-world Patient Case of Chronic GVHD -- Intervene at the First Signs of Initial Systemic Treatment Failure
    Incyte

    Seating available on first-come, first served basis
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: An FDA approved treatment option for anemia in LR-MDS
    Bristol Myers Squibb

    Seating available on first-come, first served basis
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: Dual Immunotherapy + Platinum-Based Chemotherapy for the Treatment of mNSCLCm & Treatment Option for Unresectable Hepatocellular Carcinoma
    AstraZeneca

    Seating is available on first-come, first-served basis
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: Treatment of Adults with Certain BRAF Mutation Positive Metastatic Cancers
    Pfizer Oncology

    Seating is available on first-come, first-served basis
  • 12:30 PM – 1:00 PM ET
    APSHO Committee Meet & Greet: Meet the APSHO Board of Directors
  • 1:15 PM – 1:45 PM ET
    APSHO Committee Meet & Greet: Professional Development & Leadership Committee (PD&L)
  • 1:45 PM – 2:45 PM ET
    Staying Abreast of New Biomarkers in Hematology/Oncology
  • 1:45 PM – 2:45 PM ET
    Supportive Care and Coordination of Patients Receiving Immune Effector Cell Therapies: Strategies for Advanced Practitioners
  • 2:45 PM – 3:45 PM ET
    Exhibit Hall Open & Refreshment Break
  • 3:00 PM – 3:30 PM ET
    APSHO Committee Meet & Greet: Research & Quality Improvement Committee (RQI)
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation
    Janssen invites you to learn more about a treatment option for patients diagnosed with Multiple Myeloma who are Relapsed/Refractory and have received >=4 prior lines of therapy
    Janssen Oncology part of the Pharmaceutical Companies of Johnson & Johnson
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation: Discover a treatment option for certain patients with ESR1-mutated mBC
    Stemline Therapeutics
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation: Practical Management of AML with a BCL2 Inhibitor
    AbbVie, US Medical Affairs
  • 3:45 PM – 4:45 PM ET
    New Drug Updates: Investigational Therapeutics in the Pipeline
  • 3:45 PM – 4:45 PM ET
    What’s Circulating? The Future of Cancer Detection and Treatment
  • 3:45 PM – 5:00 PM ET
    AP Talk: Peer Roundtables
  • 5:00 PM – 5:45 PM ET
    Independent Certified Satellite Symposium Current and Emerging Treatment Strategies in Multiple Myeloma
  • 5:45 PM – 6:30 PM ET
    >Independent Certified Satellite Symposium The Role of APs in the Treatment of NSCLC: Facilitating Effective Multidisciplinary Patient Management Strategies
  • Sunday, November 12, 2023
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: CARVYKTI® Product Summary for Patient Care Teams
    Janssen: Pharmaceutical Companies of Johnson & Johnson

    Seating is available on first-come, first-served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Diving Deep into Venetoclax Fixed Treatment Duration Regimens and Time off Treatment
    AbbVie, US Medical Affairs

    Seating is available on first-come, first-served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: ICLUSIG®(ponatinib): Taking Action At The Critical Moment
    Takeda

    Seating is available on first-come, first-served basis
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium
    Standardizing Extended Endocrine Therapy Decisions: A Panel Discussion on Strategies to Avoid Under- and Over-Treatment in HR+, Early-Stage Breast Cancer
    Biotheranostics Inc.

    Seating available on first-come, first-served basis
  • 6:30 AM – 12:00 PM ET
    Registration
  • 7:00 AM – 8:00 AM ET
    Continental Breakfast
  • 8:00 AM – 9:00 AM ET
    New Drug Updates in Hematologic Malignancies
  • 9:15 AM – 10:15 AM ET
    Crossroads of Cancer Care and Endocrine Toxicities
  • 9:15 AM – 10:15 AM ET
    Integrating Immunotherapy and Precision Medicine Into the Treatment of Head and Neck Cancers
  • 10:15 AM – 10:30 AM ET
    Refreshment Break
  • 10:30 AM – 11:15 AM ET
    Diversity, Equity, and Inclusion Considerations in Precision Oncology
  • 10:30 AM – 11:15 AM ET
    Improving Prostate Cancer Patient Care in the Clinical Setting
  • 11:15 AM – 12:15 PM ET
    Bringing Up Hospice Doesn't Have to be Uncomfortable: Clinical Pearls for Your Practice
  • 12:15 PM ET
    Conference Concludes
  • Monday, November 20, 2023
  • 8:00 AM – 9:00 AM ET
    New Drug Updates in Hematologic Malignancies
  • 8:10 AM – 9:15 AM ET
    Opening Panel Discussion
    Advanced Practitioners in Hematology and Oncology: A Call to Action
  • 8:25 AM – 9:00 AM ET
    The Annual Mary Pazdur Award Recipient Lecture
  • 9:15 AM – 10:15 AM ET
    Crossroads of Cancer Care and Endocrine Toxicities
  • 9:15 AM – 10:15 AM ET
    Essence of Surgical Oncology: Knowing When and When Not to Operate on Patients With Cancer
  • 9:15 AM – 10:15 AM ET
    Integrating Immunotherapy and Precision Medicine Into the Treatment of Head and Neck Cancers
  • 9:15 AM – 10:15 AM ET
    New Drug Updates: Solid Tumors
  • 9:30 AM – 10:15 AM ET
    Optimizing the Care of Patients with Colorectal Cancer in Clinical Practice
  • 9:30 AM – 10:15 AM ET
    The Evolving Landscape of Frontline Therapy in Chronic Lymphocytic Leukemia
  • 10:30 AM – 11:15 AM ET
    Diversity, Equity, and Inclusion Considerations in Precision Oncology
  • 10:30 AM – 11:15 AM ET
    Improving Prostate Cancer Patient Care in the Clinical Setting
  • 11:15 AM – 12:15 PM ET
    Advancing Precision-Targeted Treatment for Patients with Metastatic Non-Small Cell Lung Cancer
  • 11:15 AM – 12:15 PM ET
    Benign Hematology Limbo: How Low Is Too Low?
  • 11:15 AM – 12:15 PM ET
    Bringing Up Hospice Doesn't Have to be Uncomfortable: Clinical Pearls for Your Practice
  • 11:15 AM – 12:15 PM ET
    Cardio-Oncology Considerations in Patients With Cancer
  • 11:15 AM – 12:15 PM ET
    Improving Outcomes for Women with Metastatic HER2-Positive Breast Cancer
  • 1:45 PM – 2:45 PM ET
    Keynote Address: We the Patients
  • 1:45 PM – 2:45 PM ET
    Staying Abreast of New Biomarkers in Hematology/Oncology
  • 1:45 PM – 2:45 PM ET
    Supportive Care and Coordination of Patients Receiving Immune Effector Cell Therapies: Strategies for Advanced Practitioners
  • 3:45 PM – 4:30 PM ET
    Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs
  • 3:45 PM – 4:30 PM ET
    Unveiling the Impact of Radiation Therapy: Navigating Acute and Long-Term Side Effects for Optimal Patient Care
  • 3:45 PM – 4:45 PM ET
    New Drug Updates: Investigational Therapeutics in the Pipeline
  • 3:45 PM – 4:45 PM ET
    What’s Circulating? The Future of Cancer Detection and Treatment